Effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) on urinary glucose excretion in type 2 diabetes

The University of Adelaide0 个研究点目标入组 20 人开始时间: 2023年11月16日最近更新: 2024年6月10日

试验速览

暂无简介。

•Type 2 diabetes (American Diabetes Association criteria) treated by diet and/or up to two oral glucose-lowering agents (on stable doses over the last 3 months) except for SGLT2 inhibitors or DPP-4 inhibitors
•- Body mass index (BMI) between 20 to 40 kg/m2
•- Males and females, aged from 18 to 79 years
•- Glycated haemoglobin (HbA1c) between 6.0% to 10.0%
•- Haemoglobin above the lower limit of the normal range (ie. above 135 g/L for men and 115 g/L for women), and ferritin above the lower limit of normal (ie. above 30 mg/mL for men and 20 mg/mL for women)

•- Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes on a daily basis
•- History of any form of heart disease or symptoms of syncope or pre-syncope (including feeling lightheaded or dizzy, feeling unsteady when standing, unexplained falls, fainting, unexplained changes in vision, such as blurring or tunnel vision)
•- Other significant illness, including epilepsy, cardiovascular or respiratory disease
•- Impaired renal or liver function (as assessed by calculated creatinine clearance less than 60 mL/min or abnormal liver function tests (more than 2 times upper limit of normal range))
•- Donation of blood within the previous 3 months
•- Participation in any other research studies within the previous 3 months
•- Inability to give informed consent

发起方